Foley Hoag’s Government Strategies practice is active in all aspects of policymaking at the federal level. Our lawyers collaborate with our clients and the public sector to achieve mutually beneficial solutions to public policy issues. We pride ourselves on our ability to secure our clients’ strategic goals by combining a deep, substantive knowledge of issues critical to our clients’ businesses and industries with a mastery of federal legislative and regulatory processes. learn more

News more

  • Summer @ Foley Hoag LLPFoley Hoag Launches New Microsite for Law Students as 2009 On-campus Interviews Commence  [Read More]
  • Working Mother and Flex-Time Lawyers Recognize Foley Hoag  [Read More]
  • Foley Hoag Adds Noted International Investment and Trade Lawyer Mélida Hodgson to Washington, D.C. Office  [Read More]
  • Foley Hoag Joins American Lawyer's Select Group of Top 50 A-List Firms  [Read More]
  • Foley Hoag Files Amicus Brief for Biotechnology Industry Organization  [Read More]

Publications more

  • Massachusetts Determination of Need Process Expanded to Include New Green Building Standards [Read More]
  • Massachusetts Issues New Regulations Regarding the Fair Share Contribution under the Health Care Reform Law [Read More]
  • SEC Will Let Emergency Order on Prohibition of Short Selling of Financial Stocks Expire [Read More]
  • Bailout Bill Eliminates Tax Deferrals for Offshore Fund Income [Read More]
  • Economic Crisis Team Datasheet [Read More]

Events more

October 19, 2008 ACC Annual Meeting '08 [Read More] Washington State Convention & Trade Center
Seattle, WA

Client Successes more

  • Biomedical Advanced Research and Development Authority (BARDA)
    In a move that created enormous opportunities for early-stage life sciences companies, last year the U.S. Congress revitalized the federal government’s program supporting the development of medical countermeasures critical to protecting the nation against bioterrorism and pandemic threats. The resulting legislation created an agency within the Department of Health and Human Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA). BARDA will inject more than $1 billion into research, development, and procurement of vaccines, antivirals and diagnostics. BARDA enhances coordination between government and emerging companies through support of advanced research and development, the vital phase that occurs in between basic research and commercialization. On behalf of the venture capital firm, Kleiner Perkins Caulfield & Byers, Foley Hoag worked with the HHS, Congressional members, and staff to craft legislation strengthening the nation’s response to pandemic outbreaks and bioterrorism. The key financing aspect of the legislation provides much-needed funding to allow early stage companies to traverse the “valley of death” before product commercialization. The legislation authorizes the Secretary of HHS to expedite contracts and grants, and the Director of BARDA to identify areas of unmet need, spurring further innovation and investment. BARDA institutionalizes the important partnership between the federal government and the life sciences industry, critical to safety, innovation and economic vitality. [Read More]
  • Bringing Law and Science Together
    On behalf of a leading biotechnology company, our Government Strategies lawyers assembled a persuasive legal and scientific case that secured a critical federal policy decision affecting the coding and payment of important therapies for Medicare beneficiaries. [Read More]